Latest Technology Platforms News

Firebird Metals has locked in exclusive global rights to five critical LMFP patents, solidifying its position in the lithium-ion battery materials market and paving the way for its Australian Demonstration Plant.

Sky Network Television posts a robust first half FY26 with 8% revenue growth and a 77% rise in underlying net profit, driven by the strategic acquisition and integration of Discovery NZ, now Sky Free.

RocketDNA Ltd reported a 6% increase in revenue to AUD 76.83 million for the year ended 31 December 2025, expanding its autonomous drone footprint across Australia and Africa while securing major mining contracts.

Vitura Health Limited reported an 8.3% rise in half-year revenues to $67.87 million, driven by medicinal cannabis sales and telehealth services, yet posted a consolidated loss of $986,341 due to margin pressures and increased costs. Leadership changes and strategic investments mark a pivotal phase for the digital health and medicinal cannabis player.

Appen Limited has reported a slight revenue decline and a notable increase in net loss for the 2025 financial year, prompting the company to withhold its final dividend.

Pharmx Technologies reported a 3.1% revenue increase to $3.89 million for H1 FY26 but posted a net loss of $512,000 driven by strategic investments. The company also announced a significant multi-year alliance with Sigma Healthcare.

Wisr Limited reports robust half-year growth with a 23% increase in its loan book and a 14% rise in revenue, setting the stage for expected cash profitability in the second half of FY26.

Meridian Energy has reported a robust turnaround with a NZD 227 million net profit after tax for the first half of 2026, driven by record wind generation and strong hydro inflows. The company also raised its interim dividend and advanced multiple renewable projects.

Calix Limited reported a solid 21% revenue increase for the half-year ending December 2025, but losses ballooned by 250%, raising questions about the path to profitability.

Clarity Pharmaceuticals reports another metastatic prostate cancer patient achieving undetectable disease markers in its Phase II SECuRE trial, reinforcing promising efficacy and safety of its Cu-SAR-bisPSMA radiopharmaceutical.

PolyNovo Limited reported a robust 25.2% increase in half-year revenue to A$75 million, driven by strong U.S. sales and product growth, despite a near break-even net profit impacted by a manufacturing slowdown and a fire at its R&D lab.

Aristocrat Leisure reported robust FY25 results with double-digit revenue and profit growth, underpinned by strategic divestments and investments in AI. The company’s FY26 outlook remains positive, driven by market share gains and new product launches.